{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:31:09Z","timestamp":1787286669201,"version":"build-2736575974"},"reference-count":200,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100023674","name":"Deanship of Scientific Research, King Khalid University","doi-asserted-by":"publisher","award":["RGP.02\/725\/46"],"award-info":[{"award-number":["RGP.02\/725\/46"]}],"id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.seminoncol.2025.152434","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:43:26Z","timestamp":1761810206000},"page":"152434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Nanoparticle-based approaches for doxorubicin delivery in hepatocellular carcinoma: Current strategies and emerging innovations"],"prefix":"10.1016","volume":"53","author":[{"given":"Ali G.","family":"Alkhathami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman T.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hussn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"RenukaJyothi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajashree","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein Riyadh Abdul Kareem","family":"Al-Hetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansi","family":"Negi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushkar","family":"Jassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathi Jihad","family":"Hammady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah Abdulhadi","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seminoncol.2025.152434_bib0001","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1309\/AC1M-4TY4-U0TN-EN7T","article-title":"Expression of P-glycoprotein in hepatocellular carcinoma. a determinant of chemotherapy response","volume":"113","author":"Ng","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0002","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ijc.1498","article-title":"Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma","volume":"94","author":"Nies","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0003","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/381602","article-title":"TOP2A amplification and overexpression in hepatocellular carcinoma tissues","volume":"2015","author":"Panvichian","year":"2015","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0378-1119(01)00554-6","article-title":"Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha","volume":"272","author":"Okada","year":"2001","journal-title":"Gene"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0005","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00280-004-0767-4","article-title":"Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line","volume":"53","author":"Chan","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0006","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.canlet.2015.03.001","article-title":"WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation","volume":"361","author":"Liu","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0007","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.3390\/nu15102259","article-title":"p53 at the crossroads between doxorubicin-induced cardiotoxicity and resistance: a nutritional balancing act","volume":"15","author":"Guo","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0008","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.canlet.2004.10.051","article-title":"Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression","volume":"224","author":"Notarbartolo","year":"2005","journal-title":"Cancer Lett"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0009","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/cells7100177","article-title":"Targeting DNA binding for NF-\u03bab as an anticancer approach in hepatocellular Carcinoma","volume":"7","author":"Chung","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0010","article-title":"Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the \u03b2-catenin\/TCF complex association via FOXO3a activation","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0011","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1002\/jcb.26107","article-title":"Long noncoding RNA lncARSR promotes doxorubicin resistance in hepatocellular carcinoma via modulating PTEN-PI3K\/Akt pathway","volume":"118","author":"Li","year":"2017","journal-title":"J Cell Biochem"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152434_bib0012","first-page":"78","article-title":"Exosomal miR-93 derived from hepatocellular carcinoma cells promotes sorafenib resistance of hepatocellular carcinoma through PTEN\/PI3K\/Akt pathway","volume":"29","author":"Li","year":"2024","journal-title":"Cellular Molecul Biol Lett"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0013","article-title":"Role of sirtuins in hepatocellular carcinoma progression and multidrug resistance: mechanistical and pharmacological perspectives","volume":"212","author":"Ceballos","year":"2023","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0014","doi-asserted-by":"crossref","first-page":"155673","DOI":"10.1016\/j.phymed.2024.155673","article-title":"Research progress on the role and mechanism of Sirtuin family in doxorubicin cardiotoxicity","volume":"129","author":"Zhang","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078675","article-title":"The enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance","volume":"8","author":"Chow","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0016","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3390\/cells9061331","article-title":"Cancer stem cell functions in hepatocellular carcinoma and comprehensive therapeutic strategies","volume":"9","author":"Liu","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0017","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","article-title":"Nanomedicine in cancer therapy","volume":"8","author":"Fan","year":"2023","journal-title":"Signal TransductTargeted Ther"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0018","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1166\/jbn.2022.3315","article-title":"Carrier-Free Nanomedicine for Cancer immunotherapy","volume":"18","author":"Fu","year":"2022","journal-title":"J Biomed Nanotechnol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0019","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41401-020-0448-9","article-title":"Cancer nanomedicine meets immunotherapy: opportunities and challenges","volume":"41","author":"Sun","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0020","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.7150\/thno.87854","article-title":"Stimuli-activatable nanomedicine meets cancer theranostics","volume":"13","author":"Li","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0021","first-page":"147","article-title":"Cancer nanomedicine toward clinical translation: obstacles, opportunities, and future prospects","volume":"4","author":"Zhang","year":"2023","journal-title":"Med (NY, N.Y.)"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0022","article-title":"Photoactivatable protherapeutic nanomedicine for cancer","volume":"32","author":"Zhang","year":"2020","journal-title":"Adv Materials (Deerfield Beach, Fla)"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0023","first-page":"314","article-title":"[Recent progress in nanomedicine for hepatocellular carcinoma therapy]","volume":"35","author":"Xiong","year":"2018","journal-title":"Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0024","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1038\/s41467-023-41438-9","article-title":"Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8(+) T cells to boost anti-PD-1 therapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0025","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3109\/03639045.2016.1160103","article-title":"Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin","volume":"42","author":"Zhang","year":"2016","journal-title":"Drug Development Industrial Pharm"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0026","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2019.08.016","article-title":"Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma","volume":"69","author":"Elnaggar","year":"2021","journal-title":"Sem Cancer Biol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0027","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.2147\/IJN.S460329","article-title":"Dual-drug loaded nanobubbles combined with sonodynamic and chemotherapy for hepatocellular carcinoma therapy","volume":"19","author":"Guo","year":"2024","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0028","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.actbio.2022.09.035","article-title":"Isoginkgetin synergizes with doxorubicin for robust co-delivery to induce autophagic cell death in hepatocellular carcinoma","volume":"153","author":"Wang","year":"2022","journal-title":"Acta biomaterialia"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0029","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.2147\/IJN.S453709","article-title":"Nanoparticle\/engineered bacteria based triple-strategy delivery system for enhanced hepatocellular carcinoma cancer therapy","volume":"19","author":"Yang","year":"2024","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0030","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.nano.2017.05.010","article-title":"MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma","volume":"13","author":"Zhao","year":"2017","journal-title":"Nanomed: Nanotechnol, Biol, Med"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0031","first-page":"4503","article-title":"Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma","volume":"30","author":"Hoffmann","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0032","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1093\/carcin\/bgn223","article-title":"Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling","volume":"29","author":"Hu","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0033","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1471-230X-12-160","article-title":"Gene and functional up-regulation of the BCRP\/ABCG2 transporter in hepatocellular carcinoma","volume":"12","author":"Sukowati","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0034","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbrc.2019.08.116","article-title":"Dysregulation of the miR-325-3p\/DPAGT1 axis supports HBV-positive HCC chemoresistance","volume":"519","author":"Li","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/17425255.2021.1887139","article-title":"The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer","volume":"17","author":"Wang","year":"2021","journal-title":"Expert Opinion Drug Metabol Toxicol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0036","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2174\/0929867325666180105103637","article-title":"ABC transporters: regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma","volume":"26","author":"Ceballos","year":"2019","journal-title":"Current Medicin Chem"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0037","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1124\/mol.104.001701","article-title":"Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A","volume":"67","author":"Ejendal","year":"2005","journal-title":"Molecular Pharmacol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0038","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2174\/1871520615666150113103439","article-title":"Development of fourth generation ABC inhibitors from natural products: a novel approach to overcome cancer multidrug resistance","volume":"15","author":"Karthikeyan","year":"2015","journal-title":"Anti-Cancer Agents Med Chem"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0039","first-page":"641","article-title":"Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best practice & research","volume":"17","author":"Ross","year":"2004","journal-title":"Clinical Haematol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1476-4598-12-119","article-title":"MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma","volume":"12","author":"Wang","year":"2013","journal-title":"Molecul Cancer"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0041","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.7150\/ijbs.86227","article-title":"cDCBLD2 mediates sorafenib resistance in hepatocellular carcinoma by sponging miR-345-5p binding to the TOP2A coding sequence","volume":"19","author":"Ruan","year":"2023","journal-title":"Int J Biolog Sci"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0042","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/ijc.23968","article-title":"TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance","volume":"124","author":"Wong","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0043","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mrgentox.2013.06.009","article-title":"Multinucleation regulated by the Akt\/PTEN signaling pathway is a survival strategy for HepG2 cells","volume":"755","author":"Mukherjee","year":"2013","journal-title":"Mutation research"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112798","article-title":"Emerging therapies for hepatocellular carcinoma (HCC)","volume":"14","author":"Chakraborty","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0045","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1565","article-title":"Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition","volume":"11","author":"Kong","year":"2019","journal-title":"Sci Translation Med"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155089","article-title":"Andrographolide causes p53-independent HCC cell death through p62 accumulation and impaired DNA damage repair","volume":"121","author":"Li","year":"2023","journal-title":"Phytomed: Int J Phytother Phytopharmacol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0047","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.7150\/jca.70282","article-title":"Noxa and Puma genes regulated by hTERT promoter can mitigate growth and induce apoptosis in hepatocellular carcinoma mouse model","volume":"13","author":"Zhao","year":"2022","journal-title":"J Cancer"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0048","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7150\/ijbs.52517","article-title":"miR-26b enhances the sensitivity of hepatocellular carcinoma to doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy","volume":"17","author":"Chen","year":"2021","journal-title":"Int J Biolog Sci"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0049","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.canlet.2015.03.001","article-title":"WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation","volume":"361","author":"Liu","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/cr.2010.183","article-title":"NF-\u03bab and STAT3 - key players in liver inflammation and cancer","volume":"21","author":"He","year":"2011","journal-title":"Cell Res"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0051","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1476-4598-13-35","article-title":"MicroRNA-26b suppresses the NF-\u03bab signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3","volume":"13","author":"Zhao","year":"2014","journal-title":"Molecul Cancer"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0052","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41420-023-01424-y","article-title":"Blocking the CXCL1-CXCR2 axis enhances the effects of doxorubicin in HCC by remodelling the tumour microenvironment via the NF-\u03bab\/IL-1\u03b2\/CXCL1 signalling pathway","volume":"9","author":"Zhao","year":"2023","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0053","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2893.2011.01463.x","article-title":"Involvement of the NF-\u03bab pathway in multidrug resistance induced by HBx in a hepatoma cell line","volume":"18","author":"Liu","year":"2011","journal-title":"J Viral Hepatitis"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0054","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s11262-017-1479-2","article-title":"HBV X protein induces overexpression of HERV-W env through NF-\u03bab in HepG2 cells","volume":"53","author":"Liu","year":"2017","journal-title":"Virus Genes"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41420-021-00562-5","article-title":"Implication of human endogenous retrovirus W family envelope in hepatocellular carcinoma promotes MEK\/ERK-mediated metastatic invasiveness and doxorubicin resistance","volume":"7","author":"Zhou","year":"2021","journal-title":"Cell Death Discovery"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0056","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41419-019-2053-8","article-title":"miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells","volume":"10","author":"Zhou","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0057","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2217\/hep.15.41","article-title":"Mechanisms of doxorubicin resistance in hepatocellular carcinoma","volume":"3","author":"Cox","year":"2016","journal-title":"Hepatic Oncol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0058","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1535-7163.MCT-07-0397","article-title":"Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells","volume":"7","author":"Hui","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0059","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/cdd.2015.125","article-title":"Serine 574 phosphorylation alters transcriptional programming of FOXO3 by selectively enhancing apoptotic gene expression","volume":"23","author":"Li","year":"2016","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0060","unstructured":"Cox, J., Vittal, A., ONeil, M., et al. (2014). Nuclear to cytoplasmic translocation of FOXO3 determines the sensitivity of Human hepatocellular carcinoma to doxorubicin: 1418. 60, 880A."},{"key":"10.1016\/j.seminoncol.2025.152434_bib0061","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030746","article-title":"Elevated PDK1 expression drives PI3K\/AKT\/MTOR signaling promotes radiation-resistant and dedifferentiated phenotype of hepatocellular carcinoma","volume":"9","author":"Bamodu","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0062","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s41467-024-45548-w","article-title":"The transcription factor ChREBP orchestrates liver carcinogenesis by coordinating the PI3K\/AKT signaling and cancer metabolism","volume":"15","author":"Benichou","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0063","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41419-021-03596-w","article-title":"The fatty acid receptor CD36 promotes HCC progression through activating src\/PI3K\/AKT axis-dependent aerobic glycolysis","volume":"12","author":"Luo","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0064","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jpha.2023.03.006","article-title":"Ginsenoside Rk3 is a novel PI3K\/AKT-targeting therapeutics agent that regulates autophagy and apoptosis in hepatocellular carcinoma","volume":"13","author":"Qu","year":"2023","journal-title":"J Pharmaceut Analy"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0065","doi-asserted-by":"crossref","unstructured":"Choi, J., Yip-Schneider, M., Albertin, F., Wiesenauer, C., Wang, Y. & Schmidt, C. M. J. J. o. S. R. (2008). The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC. 150, 219-226.","DOI":"10.1016\/j.jss.2008.01.029"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0066","first-page":"1663","volume":"12","author":"Marin","year":"2020","journal-title":"Molecul Bases Drug Resistance Hepatocellular Carcinoma"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0067","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2147\/DDDT.S354205","article-title":"Clotrimazole inhibits HCC migration and invasion by modulating the ERK-p65 signaling pathway","volume":"16","author":"Liu","year":"2022","journal-title":"Drug Design, Develop Ther"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0068","doi-asserted-by":"crossref","unstructured":"Liu, L., Cao, Y., Chen, C., et al. (2006). Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. 66, 11851-11858.","DOI":"10.1158\/0008-5472.CAN-06-1377"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0069","doi-asserted-by":"crossref","unstructured":"Ho, K.-K., McGuire, V. A., Koo, C.-Y., et al. (2012). Phosphorylation of FOXO3a on ser-7 by p38 promotes its nuclear localization in response to doxorubicin. 287, 1545-1555.","DOI":"10.1074\/jbc.M111.284224"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0070","doi-asserted-by":"crossref","unstructured":"Zhou, J., Wan, B., Liu, X.-M., et al. (.2012). MK5 is degraded in response to doxorubicin and negatively regulates doxorubicin-induced apoptosis in hepatocellular carcinoma cells. 427, 581-586.","DOI":"10.1016\/j.bbrc.2012.09.101"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0071","doi-asserted-by":"crossref","unstructured":"Wang, J.-X., Yi, Y., Li, Y.-W., et al.. (2014). Down-regulation of sirtuin 3 is associated with poor prognosis in hepatocellular carcinoma after resection. 14, 1-9.","DOI":"10.1186\/1471-2407-14-297"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0072","doi-asserted-by":"crossref","unstructured":"Ceballos, M. P., Angel, A., Delprato, C. B., et al.. (2021). Sirtuin 1 and 2 inhibitors enhance the inhibitory effect of sorafenib in hepatocellular carcinoma cells. 892, 173736.","DOI":"10.1016\/j.ejphar.2020.173736"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0073","doi-asserted-by":"crossref","unstructured":"Chan, H.-Y., Ramasamy, T. S., Chung, F. F.-L., Teow, S.-Y. J. C. B. & Biophysics (2024). Role of sirtuin 1 (SIRT1) in regulation of autophagy and nuclear factor-kappa beta (NF-\u0138\u03b2) pathways in sorafenib-resistant hepatocellular carcinoma (HCC). 82, 959-968.","DOI":"10.1007\/s12013-024-01247-3"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0074","doi-asserted-by":"crossref","unstructured":"Lammer, J., Malagari, K., Vogl, T., et al.. (2010). Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. 33, 41-52.","DOI":"10.1007\/s00270-009-9711-7"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0075","doi-asserted-by":"crossref","unstructured":"Khongkow, M., Olmos, Y., Gong, C., et al.(2013). SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. 34, 1476-1486.","DOI":"10.1093\/carcin\/bgt098"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0076","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29894","article-title":"Small HBV surface antigen drives regorafenib resistance in HCC via KIAA1429-dependent m6A modification of CCR9","volume":"96","author":"Lv","year":"2024","journal-title":"J Med Virol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0077","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41419-023-06412-9","article-title":"Epigenetic addition of m5C to HBV transcripts promotes viral replication and evasion of innate antiviral responses","volume":"15","author":"Ding","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0078","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41575-021-00508-3","article-title":"Cancer stem cells in hepatocellular carcinoma\u2014From origin to clinical implications","volume":"19","author":"Lee","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0079","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4254\/wjh.v2.i3.114","article-title":"Hepatic cancer stem cells and drug resistance: relevance in targeted therapies for hepatocellular carcinoma","volume":"2","author":"Sukowati","year":"2010","journal-title":"World J Hepatol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-12-584","article-title":"Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation","volume":"12","author":"Zeng","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0081","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/hep.23692","article-title":"Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4\u2013AKT\u2013ATP-binding cassette G2 pathway","volume":"52","author":"Wang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0082","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/sj.onc.1210811","article-title":"CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt\/PKB survival pathway","volume":"27","author":"Ma","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0083","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1172\/JCI42550","article-title":"CD13 is a therapeutic target in human liver cancer stem cells","volume":"120","author":"Haraguchi","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0084","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrgastro.2017.169","article-title":"Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0085","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1158\/0008-5472.CAN-10-0145","article-title":"MiR-199a-3p regulates mTOR and c-met to influence the doxorubicin sensitivity of human hepatocarcinoma cells","volume":"70","author":"Fornari","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0086","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.3892\/mmr.2015.4012","article-title":"MicroRNA-215 is upregulated by treatment with Adriamycin and leads to the chemoresistance of hepatocellular carcinoma cells and tissues","volume":"12","author":"Wang","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0087","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.3995","article-title":"In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A\/p21, PTEN, AKT3 and TIMP2","volume":"227","author":"Fornari","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0088","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.arcmed.2011.06.008","article-title":"MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN","volume":"42","author":"Wang","year":"2011","journal-title":"Arch Med Res"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0089","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.ajpath.2012.02.024","article-title":"Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298","volume":"180","author":"Bao","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0090","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s10495-008-0256-z","article-title":"Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3","volume":"13","author":"Tsang","year":"2008","journal-title":"Apoptosis: Int J Programmed Cell Death"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0091","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10549-015-3372-9","article-title":"miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer","volume":"151","author":"Hu","year":"2015","journal-title":"Breast Can Res Treat"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0092","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s12032-014-0972-x","article-title":"MiR-34c inhibits osteosarcoma metastasis and chemoresistance","volume":"31","author":"Xu","year":"2014","journal-title":"Med Oncol (Northwood, London, England)"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0093","doi-asserted-by":"crossref","first-page":"9472","DOI":"10.18632\/oncotarget.2418","article-title":"miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma","volume":"5","author":"Xu","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0094","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbrc.2015.02.101","article-title":"MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1","volume":"459","author":"Zhang","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0095","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.3892\/mmr.2015.3890","article-title":"MicroRNA-522 reverses drug resistance of doxorubicin-induced HT29 colon cancer cell by targeting ABCB5","volume":"12","author":"Yang","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0096","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.bbrc.2015.06.041","article-title":"MicroRNA-101 down-regulates sphingosine kinase 1 in colorectal cancer cells","volume":"463","author":"Chen","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0097","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/jcp.24366","article-title":"MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA","volume":"230","author":"Qu","year":"2015","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0098","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1038\/onc.2013.297","article-title":"miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1","volume":"33","author":"Shang","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0099","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1007\/s13277-014-2835-7","article-title":"miR-103\/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1","volume":"36","author":"Zhang","year":"2015","journal-title":"Tumour Biol: J Int Society Oncodevelopmental Biol Med"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0100","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.leukres.2009.10.002","article-title":"miR-138 might reverse multidrug resistance of leukemia cells","volume":"34","author":"Zhao","year":"2010","journal-title":"Leukemia Res"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0101","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s13402-024-00955-5","article-title":"SPG21, a potential oncogene targeted by miR-128-3p, amplifies HBx-induced carcinogenesis and chemoresistance via activation of TRPM7-mediated JNK pathway in hepatocellular carcinoma","volume":"47","author":"Zhou","year":"2024","journal-title":"Cell Oncol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0102","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.3748\/wjg.v27.i48.8302","article-title":"Hepatitis B core antigen modulates exosomal miR-135a to target vesicle-associated membrane protein 2 promoting chemoresistance in hepatocellular carcinoma","volume":"27","author":"Wei","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41419-020-03318-8","article-title":"LncRNA DANCR represses doxorubicin-induced apoptosis through stabilizing MALAT1 expression in colorectal cancer cells","volume":"12","author":"Xiong","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0104","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1186\/s13019-024-03129-4","article-title":"LncRNA CASC9 facilitates papillary thyroid cancer development and doxorubicin resistance via miR-28-3p\/BCL-2 axis and PI3K\/AKT signaling pathway","volume":"19","author":"Yu","year":"2024","journal-title":"J Cardiothoracic Surg"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0105","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1515\/biol-2020-0086","article-title":"LncRNA SNHG15 contributes to doxorubicin resistance of osteosarcoma cells through targeting the miR-381-3p\/GFRA1 axis","volume":"15","author":"Zhang","year":"2020","journal-title":"Open life sciences"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0106","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.18632\/aging.103004","article-title":"LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142\/miR-22","volume":"12","author":"Zhu","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0107","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/1440-1681.13307","article-title":"LncRNA XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR-200c-3p to upregulate ANLN","volume":"47","author":"Zhang","year":"2020","journal-title":"Clin Experiment Pharmacol Physiol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0108","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/s41388-024-02972-y","article-title":"LINC00460-FUS-MYC feedback loop drives breast cancer metastasis and doxorubicin resistance","volume":"43","author":"Yang","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0109","doi-asserted-by":"crossref","first-page":"8589","DOI":"10.1111\/jcmm.15487","article-title":"LINC00160 mediated paclitaxel-and doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C\/ebp\u03b2","volume":"24","author":"Wu","year":"2020","journal-title":"J Cell Molecul Med"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0110","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/15384047.2018.1449610","article-title":"LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3\/INO80 pathway","volume":"19","author":"Wang","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0111","article-title":"LINC01977 Promotes breast cancer progression and chemoresistance to doxorubicin by targeting miR-212-3p\/GOLM1 axis","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0112","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11010-020-03904-6","article-title":"LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p\/Nova1 axis","volume":"476","author":"Cao","year":"2021","journal-title":"Molecular Cellular Biochem"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0113","first-page":"435","article-title":"Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K\/AKT\/mTOR signaling pathway","volume":"18","author":"Li","year":"2019","journal-title":"Experimental Therapeutic Med"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0114","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1002\/jcp.29585","article-title":"Exosome-mediated transfer of long noncoding RNA H19 induces doxorubicin resistance in breast cancer","volume":"235","author":"Wang","year":"2020","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0115","doi-asserted-by":"crossref","first-page":"13159","DOI":"10.2147\/OTT.S255113","article-title":"Interactions between lncRNA TUG1 and miR-9-5p modulate the resistance of breast cancer cells to doxorubicin by regulating eIF5A2","volume":"13","author":"Wang","year":"2020","journal-title":"OncoTargets Therapy"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0116","article-title":"Knockdown of the long noncoding RNA PURPL induces apoptosis and sensitizes liver cancer cells to doxorubicin","volume":"12","author":"Berhane","year":"2022","journal-title":"Scientific Rep"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0117","doi-asserted-by":"crossref","first-page":"71881","DOI":"10.18632\/oncotarget.17985","article-title":"LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1","volume":"8","author":"Kun-Peng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0118","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/1120009X.2022.2082348","article-title":"LncRNA-IQCH-AS1 sensitizes thyroid cancer cells to doxorubicin via modulating the miR-196a-5p\/PPP2R1B signalling pathway","volume":"35","author":"Fei","year":"2023","journal-title":"J Chemother (Florence, Italy)"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0119","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/09205063.2024.2410060","article-title":"In vivo delivery of PBAE\/ZIF-8 enhances the sensitivity of colorectal cancer to doxorubicin through sh-LncRNA ASB16-AS1","volume":"36","author":"Yang","year":"2025","journal-title":"J Biomaterials Science"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152434_bib0120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1615\/CritRevEukaryotGeneExpr.2014007702","article-title":"Aberrant regulation of alternative pre-mRNA splicing in hepatocellular carcinoma","volume":"24","author":"Liu","year":"2014","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0121","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/hep.25834","article-title":"Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation","volume":"56","author":"Liu","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0122","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.3390\/ijms24043263","article-title":"HBV enhances sorafenib resistance in hepatocellular carcinoma by reducing ferroptosis via SRSF2-mediated abnormal PCLAF splicing","volume":"24","author":"Liu","year":"2023","journal-title":"Int J Molecul Sci"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0123","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.1158\/1078-0432.CCR-20-0389","article-title":"Stimulation of oncogene-specific tumor-infiltrating T cells through combined vaccine and \u03b1pd-1 enable sustained antitumor responses against established HER2 breast cancer","volume":"26","author":"Crosby","year":"2020","journal-title":"Clin Can Res"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0124","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2019.02.016","article-title":"CXCL11 promotes self-renewal and tumorigenicity of \u03b12\u03b41+ liver tumor-initiating cells through CXCR3\/ERK1\/2 signaling","volume":"449","author":"Zhang","year":"2019","journal-title":"Cancer lett"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0125","article-title":"Synergistic nanomedicine: photodynamic, photothermal and photoimmune therapy in hepatocellular carcinoma: fulfilling the myth of Prometheus?","volume":"24","author":"Ailioaie","year":"2023","journal-title":"Int j molecul sci"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0126","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1166\/jbn.2021.3055","article-title":"Nanomedicine approach to immunotherapy of hepatocellular carcinoma","volume":"17","author":"Ni","year":"2021","journal-title":"J Biomed Nanotechnol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0127","article-title":"A branched small molecule-drug conjugate nanomedicine strategy for the targeted HCC chemotherapy","volume":"228","author":"Li","year":"2022","journal-title":"Eur J Med Chemist"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0128","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1038\/s41467-023-42509-7","article-title":"Nanosensitizer-mediated augmentation of sonodynamic therapy efficacy and antitumor immunity","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0129","doi-asserted-by":"crossref","DOI":"10.1016\/j.mtbio.2023.100766","article-title":"Exploiting targeted nanomedicine for surveillance, diagnosis, and treatment of hepatocellular carcinoma","volume":"22","author":"Liu","year":"2023","journal-title":"Materials Today Bio"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2020.102352","article-title":"Distinct stratification of normal liver, hepatocellular carcinoma (HCC), and anticancer nanomedicine-treated- tumor tissues by Raman fingerprinting for HCC therapeutic monitoring","volume":"33","author":"Poojari","year":"2021","journal-title":"Nanomed: Nanotechnol Biol Med"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0131","article-title":"Tailored liposomal nanomedicine suppresses incomplete radiofrequency ablation-induced tumor relapse by reprogramming antitumor immunity","volume":"14","author":"Wang","year":"2025","journal-title":"Adv Healthcare Materials"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0132","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.792781","article-title":"Combination of ablation and immunotherapy for hepatocellular carcinoma: where we are and where to go","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0133","first-page":"255","article-title":"Safety and efficacy of trans arterial chemoembolization with drug-eluting beads in hepatocellular cancer: a systematic review","volume":"59","author":"Martin","year":"2012","journal-title":"Hepato-gastroenterology"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0134","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243815","article-title":"Combined treatment of sorafenib and doxorubicin-loaded microbubble-albumin nanoparticle complex for hepatocellular carcinoma: a feasibility study","volume":"15","author":"Lee","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123087","article-title":"Nanomedicine-unlocked radiofrequency dynamic therapy dampens incomplete radiofrequency ablation-arised immunosuppression to suppress cancer relapse","volume":"317","author":"Fang","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0136","doi-asserted-by":"crossref","DOI":"10.1016\/j.mtbio.2023.100873","article-title":"Emulsifying Lipiodol with pH-sensitive DOX@HmA nanoparticles for hepatocellular carcinoma TACE treatment eliminate metastasis","volume":"23","author":"Shi","year":"2023","journal-title":"Materials today Bio"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0137","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1177\/0885328219836540","article-title":"Doxorubicin-loaded Fe(3)O(4)-ZIF-8 nano-composites for hepatocellular carcinoma therapy","volume":"33","author":"Cheng","year":"2019","journal-title":"J Biomater Applicati"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0138","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.gastha.2023.07.012","article-title":"Targeting wnt-\u03b2-catenin signaling pathway for hepatocellular carcinoma nanomedicine","volume":"2","author":"Bakrania","year":"2023","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0139","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010041","article-title":"Nanomedicine in hepatocellular carcinoma: a new frontier in targeted cancer treatment","volume":"14","author":"Bakrania","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051960","article-title":"Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats","volume":"7","author":"Golla","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0141","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/26\/2\/025102","article-title":"Multifunctional PEG modified DOX loaded mesoporous silica nanoparticle@CuS nanohybrids as photo-thermal agent and thermal-triggered drug release vehicle for hepatocellular carcinoma treatment","volume":"26","author":"Wu","year":"2015","journal-title":"Nanotechnology"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0142","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.2147\/IJN.S470847","article-title":"Ultrasound-responsive Nanodelivery system of GPC3-targeting and sonosensitizer for visualized Hepatocellular Carcinoma therapy","volume":"19","author":"Zhang","year":"2024","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0143","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2217\/nnm-2016-0402","article-title":"Biomacromolecule\/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy","volume":"12","author":"Zhang","year":"2017","journal-title":"Nanomedicine (London, England)"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0144","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.biomaterials.2017.10.047","article-title":"Shape-controlled magnetic mesoporous silica nanoparticles for magnetically-mediated suicide gene therapy of hepatocellular carcinoma","volume":"154","author":"Wang","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0145","first-page":"150","article-title":"Early response evaluation of doxorubicin-nanoparticle-microbubble therapy in orthotopic hepatocellular carcinoma rat model using contrast-enhanced ultrasound and intravoxel incoherent motion-diffusion MRI","volume":"41","author":"Yang","year":"2022","journal-title":"Ultrasonography (Seoul, Korea)"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0146","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124424","article-title":"Nano co-delivery of doxorubicin and plumbagin achieves synergistic chemotherapy of hepatocellular carcinoma","volume":"661","author":"Cao","year":"2024","journal-title":"Int J Pharmaceut"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0147","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.apsb.2016.05.011","article-title":"Charge-reversal nanoparticles: novel targeted drug delivery carriers","volume":"6","author":"Chen","year":"2016","journal-title":"Acta pharmaceutica Sinica B"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0148","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12951-021-01161-3","article-title":"Augmented EPR effect post IRFA to enhance the therapeutic efficacy of arsenic loaded ZIF-8 nanoparticles on residual HCC progression","volume":"20","author":"Chen","year":"2022","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0149","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121362","article-title":"Active targeted Janus nanoparticles enable anti-angiogenic drug combining chemotherapy agent to prevent postoperative hepatocellular carcinoma recurrence","volume":"281","author":"Zhang","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0150","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1186\/s12951-022-01703-3","article-title":"Review targeted drug delivery systems for norcantharidin in cancer therapy","volume":"20","author":"Zhai","year":"2022","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0151","article-title":"Norcantharidin inhibits TOP2A expression via H3K27me3 mediated epigenetic regulation to alleviate the progression of hepatocellular carcinoma","volume":"16","author":"Wu","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0152","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000037394","article-title":"Norcantharidin in cancer therapy\u2013a new approach to overcoming therapeutic resistance: a review","volume":"103","author":"Zeng","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0153","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1329311","article-title":"Smart nanogels for cancer treatment from the perspective of functional groups","volume":"11","author":"Yu","year":"2024","journal-title":"Front Bioengineer Biotechnol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0154","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.2147\/IJN.S308057","article-title":"Intratumoral administration of thermosensitive hydrogel co-loaded with norcantharidin nanoparticles and doxorubicin for the treatment of hepatocellular carcinoma","volume":"16","author":"Gao","year":"2021","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0155","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3390\/nu13020415","article-title":"The influence of omega-3 long-chain polyunsaturated fatty acid, docosahexaenoic acid, on child behavioral functioning: a review of randomized controlled trials of DHA supplementation in pregnancy, the neonatal period and infancy","volume":"13","author":"Gould","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0156","doi-asserted-by":"crossref","DOI":"10.1016\/j.clnesp.2024.06.053","article-title":"Role of omega-3 fatty acids eicosapentaenoic (EPA) and docosahexaenoic (DHA) as modulatory and anti-inflammatory agents in noncommunicable diet-related diseases\u2013Reports from the last 10 years","volume":"63","author":"Banaszak","year":"2024","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0157","article-title":"Functional doxorubicin-loaded omega-3 unsaturated fatty acids nanoparticles in reversing hepatocellular carcinoma multidrug resistance","volume":"27","author":"Wang","year":"2021","journal-title":"Medical Science Monitor: Int Med J Experimental Clin Res"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0158","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1002\/pat.6140","article-title":"Polycaprolactone and its derivatives for drug delivery","volume":"34","author":"Pawar","year":"2023","journal-title":"Polymers Adv Technolog"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0159","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13065-022-00888-w","article-title":"Synthesis, characterization, and cytotoxicity of doxorubicin-loaded polycaprolactone nanocapsules as controlled anti-hepatocellular carcinoma drug release system","volume":"16","author":"Fahmi","year":"2022","journal-title":"BMC Chem"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0160","first-page":"355","article-title":"Fabrication of PCL-PEG-PCL nanocarrier for Co-loading of Docetaxel\/Quercetin and assessment of its effect on growth inhibition of human liver cancer (Hep-G2) cell line","volume":"12","author":"Hakemi","year":"2021","journal-title":"Int J Nano Dimension"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0161","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.3390\/pharmaceutics14091845","article-title":"A Novel C@ Fe@ Cu nanocomposite loaded with doxorubicin tailored for the treatment of hepatocellular carcinoma","volume":"14","author":"Saddik","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0162","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12951-021-01161-3","article-title":"Augmented EPR effect post IRFA to enhance the therapeutic efficacy of arsenic loaded ZIF-8 nanoparticles on residual HCC progression","volume":"20","author":"Chen","year":"2022","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0163","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhazmat.2020.124191","article-title":"Fenton\/Fenton-like processes with in-situ production of hydrogen peroxide\/hydroxyl radical for degradation of emerging contaminants: advances and prospects","volume":"404","author":"Liu","year":"2021","journal-title":"J Hazardous Material"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0164","article-title":"Peroxymonosulfate activation by vacuum ultraviolet and trace copper ions: a new way to boost Cu (II)\/Cu (I) redox cycle","volume":"450","author":"Zhang","year":"2022","journal-title":"Chem Engineer J"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0165","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1021\/acsanm.1c00181","article-title":"Antitumor effects of pH-\/reduction-responsive Fe3O4@ alginate magnetic nanoparticles loaded with doxorubicin on subcutaneous tumor models of hepatocellular carcinoma xenografts in BALB\/c nude mice","volume":"4","author":"Peng","year":"2021","journal-title":"ACS Applied Nano Materials"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0166","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12951-022-01764-4","article-title":"Phosphorothioated amino-AS1411 aptamer functionalized stealth nanoliposome accelerates bio-therapeutic threshold of apigenin in neoplastic rat liver: a mechanistic approach","volume":"21","author":"Dhara","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0167","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/cells10071717","article-title":"In vitro cell toxicity and intracellular uptake of doxorubicin exposed as a solution or liposomes: implications for treatment of hepatocellular carcinoma","volume":"10","author":"Kullenberg","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0168","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/17425247.2021.1912008","article-title":"Metallic nanoparticles as drug delivery system for the treatment of cancer","volume":"18","author":"Desai","year":"2021","journal-title":"Expert opinion on drug delivery"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12668-024-01747-9","article-title":"Synergistic cytotoxic effects of doxorubicin loaded silver, gold and zinc oxide nanoparticles in HepG2 liver cancer cells","volume":"15","author":"Tabbasam","year":"2025","journal-title":"BioNanoScience"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0170","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/17425247.2024.2343882","article-title":"Doxorubicin conjugates: a practical approach for its cardiotoxicity alleviation","volume":"21","author":"Ibrahim","year":"2024","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0171","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181944","article-title":"Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model","volume":"12","author":"Kuruvilla","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0172","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3390\/cancers15061798","article-title":"Treatment strategy for intermediate-stage hepatocellular carcinoma: transarterial chemoembolization, systemic therapy, and conversion therapy","volume":"15","author":"Hatanaka","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0173","doi-asserted-by":"crossref","unstructured":"Liu, L., Zhuang, J., Tan, J., et al.(2022). Doxorubicin-loaded UiO-66\/bi\u2082s\u2083 nanocomposite-enhanced synergistic transarterial chemoembolization and photothermal therapy against hepatocellular carcinoma.","DOI":"10.1021\/acsami.1c19121"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0174","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12917-023-03632-1","article-title":"Nigella sativa-chitosan nanoparticles: novel intestinal mucosal immunomodulator controls and protects against Salmonella enterica serovar Enteritidis infection in broilers","volume":"19","author":"Ahmad","year":"2023","journal-title":"BMC Veterinary Res"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0175","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1080\/01635581.2020.1823436","article-title":"Ginger extract loaded into chitosan nanoparticles enhances cytotoxicity and reduces cardiotoxicity of doxorubicin in hepatocellular carcinoma in mice","volume":"73","author":"Abo Mansour","year":"2021","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0176","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.105754","article-title":"Application of glycyrrhizic acid and glycyrrhetinic acid in the drug delivery system","volume":"97","author":"Zhao","year":"2024","journal-title":"J Drug Delivery Science Technol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0177","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1007\/s13346-023-01512-7","article-title":"Anti-tumor therapy of glycyrrhetinic acid targeted liposome co-delivery of doxorubicin and berberine for hepatocellular carcinoma","volume":"14","author":"Xu","year":"2024","journal-title":"Drug Delivery Translat Res"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0178","doi-asserted-by":"crossref","first-page":"8335","DOI":"10.3390\/molecules27238335","article-title":"Isoginkgetin\u2014A natural compound to control U87MG glioblastoma cell growth and migration activating apoptosis and autophagy","volume":"27","author":"Oliva","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0179","article-title":"Preparation and characterization of photo-oxidative dual-crosslinked chitosan\/hyaluronic acid hydrogels","volume":"180","author":"Zhao","year":"2022","journal-title":"React Function Polymers"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0180","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.actbio.2022.09.035","article-title":"Isoginkgetin synergizes with doxorubicin for robust co-delivery to induce autophagic cell death in hepatocellular carcinoma","volume":"153","author":"Wang","year":"2022","journal-title":"Acta Biomaterialia"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0181","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijbiomac.2022.07.092","article-title":"Fabrication of alginate@ silver nanoparticles (Alg@ AgNPs) bionanocomposite for the sequestration of crystal violet dye from aqueous solution","volume":"218","author":"Ahmad","year":"2022","journal-title":"Int J Biolog Macromolecul"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0182","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202301352","article-title":"A sodium alginate-based multifunctional nanoplatform for synergistic chemo-immunotherapy of hepatocellular carcinoma","volume":"35","author":"Huang","year":"2023","journal-title":"Adv Materials"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0183","first-page":"1","article-title":"Plant-derived natural products as multidrug resistance modulators in cancer therapy","volume":"1","author":"Isaoglu","year":"2020","journal-title":"Anatolian J Biol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0184","first-page":"1819","article-title":"Novel norcantharidin-loaded liver targeting chitosan nanoparticles to enhance intestinal absorption","author":"Bei","year":"2012","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0185","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.biopha.2014.11.028","article-title":"Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin","volume":"69","author":"Lv","year":"2015","journal-title":"Biomed & Pharmacother = Biomed & Pharmacotherapie"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0186","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1158\/1535-7163.MCT-08-0021","article-title":"Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin","volume":"7","author":"Kovalchuk","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0187","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1475-2867-13-21","article-title":"miR-125b develops chemoresistance in Ewing sarcoma\/primitive neuroectodermal tumor","volume":"13","author":"Iida","year":"2013","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0188","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/iub.2075","article-title":"LncRNA LOXL1-AS1\/miR-let-7a-5p\/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells","volume":"71","author":"Bai","year":"2019","journal-title":"IUBMB life"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0189","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1418","article-title":"LncRNA NEAT1 suppresses cellular senescence in hepatocellular carcinoma via KIF11-dependent repression of CDKN2A","volume":"13","author":"Chen","year":"2023","journal-title":"Clin Translational Med"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0190","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3389\/fgene.2020.00566","article-title":"Integrative analysis of the doxorubicin-associated LncRNA-mRNA network identifies chemoresistance-associated lnc-TRDMT1-5 as a biomarker of breast cancer progression","volume":"11","author":"Chen","year":"2020","journal-title":"Front Genet"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0191","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/cbin.11889","article-title":"LncRNA FGD5-AS1 potentiates autophagy-associated doxorubicin resistance by regulating the miR-154-5p\/WNT5A axis in osteosarcoma","volume":"46","author":"Fei","year":"2022","journal-title":"Cell Biol Int"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0192","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/tox.23501","article-title":"LncRNA PVT1 contributes to invasion and doxorubicin resistance of bladder cancer cells through promoting MDM2 expression and AURKB-mediated p53 ubiquitination","volume":"37","author":"Jiang","year":"2022","journal-title":"Environment Toxicol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0193","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/CAD.0000000000001393","article-title":"Long noncoding RNA TUG1 decreases bladder cancer chemo-sensitivity toward doxorubicin through elevating KPNA2 expression and activating the PI3K\/AKT pathway via adsorbing miR-582-5p","volume":"34","author":"Lu","year":"2023","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0194","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12032-025-02668-7","article-title":"LncRNA CCAT1 decreases the sensitivity to doxorubicin in lung cancer cells by regulating miR-181a\/CPEB2 axis","volume":"42","author":"Muge","year":"2025","journal-title":"Med Oncol (Northwood, London, England)"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0195","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.1002\/jcb.26901","article-title":"HOTAIR enhanced paclitaxel and doxorubicin resistance in gastric cancer cells partly through inhibiting miR-217 expression","volume":"119","author":"Wang","year":"2018","journal-title":"J Cellular Biochem"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0196","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/08923973.2022.2054428","article-title":"Up-regulation of LncRNA UCA1 by TGF-\u03b2 promotes doxorubicin resistance in breast cancer cells","volume":"44","author":"Wo","year":"2022","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0197","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2023.102199","article-title":"Oncogenic lncRNA MALAT-1 recruits E2F1 to upregulate RAD51 expression and thus promotes cell autophagy and tumor growth in non-small cell lung cancer","author":"Xin","year":"2023","journal-title":"Pulmonary Pharmacol Therapeut"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0198","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1016\/j.bj.2020.11.002","article-title":"LncRNA MALAT1 promotes breast cancer progression and doxorubicin resistance via regulating miR-570-3p","volume":"44","author":"Yue","year":"2021","journal-title":"Biomed J"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0199","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2017.03.018","article-title":"Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2","volume":"396","author":"Zhang","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.seminoncol.2025.152434_bib0200","doi-asserted-by":"crossref","first-page":"91990","DOI":"10.18632\/oncotarget.21121","article-title":"LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775425001265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775425001265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:15:01Z","timestamp":1773825301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775425001265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":200,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0093775425001265"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152434","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticle-based approaches for doxorubicin delivery in hepatocellular carcinoma: Current strategies and emerging innovations","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152434","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152434"}}